Excelsior Medical Co., Ltd. (4104.TW)
TWD 86.1
(-0.35%)
TWD 86.1
(-0.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 746.6 Million TWD | 11.86% |
| 2022 | 667.45 Million TWD | 9.93% |
| 2021 | 607.14 Million TWD | 6.21% |
| 2020 | 571.67 Million TWD | 11.06% |
| 2019 | 514.75 Million TWD | 13.99% |
| 2018 | 451.56 Million TWD | 13.16% |
| 2017 | 399.04 Million TWD | 2.44% |
| 2016 | 389.55 Million TWD | 2.79% |
| 2015 | 379 Million TWD | 32.67% |
| 2014 | 285.68 Million TWD | -4.75% |
| 2013 | 299.94 Million TWD | 8.76% |
| 2012 | 275.78 Million TWD | -17.42% |
| 2011 | 333.97 Million TWD | -6.11% |
| 2010 | 355.69 Million TWD | 14.02% |
| 2009 | 311.95 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 220.37 Million TWD | 19.01% |
| 2024 Q1 | 185.17 Million TWD | -1.7% |
| 2023 Q4 | 188.38 Million TWD | 2.76% |
| 2023 Q2 | 173.07 Million TWD | -14.24% |
| 2023 Q3 | 183.31 Million TWD | 5.92% |
| 2023 FY | 746.6 Million TWD | 11.86% |
| 2023 Q1 | 201.82 Million TWD | 27.98% |
| 2022 Q2 | 140.17 Million TWD | -16.54% |
| 2022 Q3 | 201.63 Million TWD | 43.84% |
| 2022 Q4 | 157.7 Million TWD | -21.79% |
| 2022 FY | 667.45 Million TWD | 9.93% |
| 2022 Q1 | 167.94 Million TWD | -2.46% |
| 2021 FY | 607.14 Million TWD | 6.21% |
| 2021 Q3 | 167.85 Million TWD | 23.05% |
| 2021 Q4 | 172.19 Million TWD | 2.58% |
| 2021 Q1 | 130.68 Million TWD | -8.02% |
| 2021 Q2 | 136.41 Million TWD | 4.39% |
| 2020 Q2 | 145.95 Million TWD | 5.79% |
| 2020 Q1 | 137.96 Million TWD | 19.84% |
| 2020 Q3 | 145.67 Million TWD | -0.19% |
| 2020 Q4 | 142.07 Million TWD | -2.47% |
| 2020 FY | 571.67 Million TWD | 11.06% |
| 2019 Q2 | 125.57 Million TWD | -3.4% |
| 2019 Q4 | 115.12 Million TWD | -20.09% |
| 2019 FY | 514.75 Million TWD | 13.99% |
| 2019 Q1 | 129.99 Million TWD | 17.09% |
| 2019 Q3 | 144.06 Million TWD | 14.72% |
| 2018 Q4 | 111.01 Million TWD | 0.43% |
| 2018 FY | 451.56 Million TWD | 13.16% |
| 2018 Q3 | 110.54 Million TWD | -11.76% |
| 2018 Q2 | 125.27 Million TWD | 19.62% |
| 2018 Q1 | 104.72 Million TWD | 28.61% |
| 2017 Q3 | 91.22 Million TWD | -7.43% |
| 2017 Q1 | 127.84 Million TWD | 60.59% |
| 2017 Q2 | 98.54 Million TWD | -22.92% |
| 2017 FY | 399.04 Million TWD | 2.44% |
| 2017 Q4 | 81.42 Million TWD | -10.74% |
| 2016 Q1 | 130.15 Million TWD | 26.94% |
| 2016 Q2 | 85.16 Million TWD | -34.57% |
| 2016 Q3 | 94.62 Million TWD | 11.12% |
| 2016 Q4 | 79.6 Million TWD | -15.87% |
| 2016 FY | 389.55 Million TWD | 2.79% |
| 2015 Q2 | 100.67 Million TWD | 16.77% |
| 2015 Q1 | 86.21 Million TWD | 63.51% |
| 2015 FY | 379 Million TWD | 32.67% |
| 2015 Q3 | 89.56 Million TWD | -11.04% |
| 2015 Q4 | 102.53 Million TWD | 14.48% |
| 2014 Q4 | 52.72 Million TWD | -33.27% |
| 2014 Q3 | 79.01 Million TWD | 6.29% |
| 2014 Q1 | 79.59 Million TWD | 103.73% |
| 2014 FY | 285.68 Million TWD | -4.75% |
| 2014 Q2 | 74.34 Million TWD | -6.59% |
| 2013 Q3 | 86.2 Million TWD | -28.75% |
| 2013 Q1 | 53.68 Million TWD | 17.11% |
| 2013 FY | 299.94 Million TWD | 8.76% |
| 2013 Q4 | 39.06 Million TWD | -54.68% |
| 2013 Q2 | 120.98 Million TWD | 125.35% |
| 2012 Q4 | 45.84 Million TWD | -52.36% |
| 2012 Q3 | 96.22 Million TWD | 57.69% |
| 2012 Q2 | 61.01 Million TWD | -7.16% |
| 2012 FY | 275.78 Million TWD | -17.42% |
| 2012 Q1 | 65.72 Million TWD | 1.81% |
| 2011 Q2 | 78.19 Million TWD | -19.82% |
| 2011 Q1 | 97.51 Million TWD | 14.67% |
| 2011 FY | 333.97 Million TWD | -6.11% |
| 2011 Q4 | 64.55 Million TWD | -31.12% |
| 2011 Q3 | 93.71 Million TWD | 19.85% |
| 2010 Q3 | 116.29 Million TWD | 60.21% |
| 2010 FY | 355.69 Million TWD | 14.02% |
| 2010 Q4 | 85.04 Million TWD | -26.87% |
| 2010 Q1 | 81.76 Million TWD | 0.0% |
| 2010 Q2 | 72.58 Million TWD | -11.23% |
| 2009 FY | 311.95 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Medical Corp. | 152.17 Million TWD | -390.632% |
| OK Biotech Co., Ltd. | 2.94 Million TWD | -25225.814% |
| Applied BioCode Corporation | -164.19 Million TWD | 554.695% |